The effect of sumac and cinnamon on cardiovascular patients

Not Applicable

Conditions: Cardiovascular diseases (CVDs).
Cardiovascular disease, unspecified
I51.6

Registration Number: IRCT20150711023153N5

Lead Sponsor: Yasouj University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 75

Inclusion Criteria

Completing and signing the informed consent form.
Age between 20-75 years
Patients hospitalized in the cardiac intensive care unit who have MI (myocardial infarction) based on a definitive diagnosis.
Type 2 diabetes mellitus diagnosed by a doctor
Body mass index (BMI)>25
Familiarity with Persian language and the ability to read and write

Exclusion Criteria

Pregnant and lactating people or people with mental illnesses, as well as patients with stomach ulcers or digestive disorders or other disorders affecting food metabolism.
hypothyroidism or hyperthyroidism and any systemic disease (including liver, kidney, gout, rheumatoid arthritis and acute or chronic kidney failure)
Allergy to sumac or cinnamon
Users of psychotropic drugs, including antidepressants, anti-psychotics, anti-anxiety drugs
Heart failure in stage IV
Acute infections at the time of study entry
Obstructive pulmonary diseases
Treatment with sex hormones
Use of medication interfering with the study
Participation in another clinical study in the last 3 months
People with any problems in understanding and filling the consent form

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ow-density lipoprotein. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods.;High-density lipoprotein. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods - Elisa Kit.;Very-low density lipoprotein. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods.;Triglyceride. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods - Elisa Kit.;Total Cholesterol. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods - Elisa Kit.;Life Quality. Timepoint: At the beginning and end of the intervention period. Method of measurement: World Health Organization quality of life questionnaire bref.;Pain. Timepoint: At the beginning and end of the intervention period. Method of measurement: Mcgill pain questionnarie.

Secondary Outcome Measures

Name	Time	Method
Interleukin-6. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods.;High sensitive C reactive protein (hs-CRP). Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods.;Complete blood count. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods.